CHMP var af den mening, at effekten på Alzheimers demens svarede til effekten ved vaskulær / blandet demens, og at patienter med svær aggression ved vaskulær/ blandet demens af sikkerhedshensyn bør udelukkes fra behandling med risperidon.
The CHMP was of the opinion that the efficacy in Alzheimer’ s dementia was similar compared to efficacy in vascular/ mixed dementias and that patients with severe aggression in vascular/ mixed dementias should be excluded from treatment with risperidone because of safety concerns.